Cancer-Associated Venous Thromboembolism Treatment With Anti-Xa Versus Weight-Based Enoxaparin: A Retrospective Evaluation of Safety and Efficacy.
CONCLUSION AND RELEVANCE: Patients with cancer receiving anti-Xa-guided enoxaparin dose adjustments for initial VTE, compared with weight-based dosing, had no significant difference in the rate of recurrent VTE or major bleed.
PMID: 33455432 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Hart K, Andrick B, Grassi S, Manikowski J, Graham J Tags: Ann Pharmacother Source Type: research
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Electronic Health Records (EHR) | Lovenox | Study | Thrombosis